Apothecon et al.; Withdrawal of Approval of 103 New Drug Applications and 35 Abbreviated New Drug Applications; Correction, 48993 [E9-23170]
Download as PDF
<![CDATA[
jlentini on DSKJ8SOYB1PROD with NOTICES
Federal Register / Vol. 74, No. 185 / Friday, September 25, 2009 / Notices
minority groups, and physically
challenged individuals are adequately
represented on the MEDCAC. Therefore,
we encourage nominations of qualified
candidates from these groups.
All nominations must be
accompanied by curricula vitae.
Nomination packages must be sent to
Maria Ellis at the address listed in the
ADDRESSES section of this notice.
Nominees for voting membership must
also have expertise and experience in
one or more of the following fields:
• Clinical medicine of all specialties.
• Administrative medicine.
• Public health.
• Patient advocacy.
• Biologic and physical sciences.
• Health care data and information
management and analysis.
• The economics of health care.
• Medical ethics.
• Other related professions such as
epidemiology and biostatistics, and
methodology of clinical trial design.
We are looking for experts in a
number of fields. Our most critical
needs are for experts in hematology;
genomics; end of life care; Bayesian
statistics; clinical epidemiology; clinical
trial methodology; knee, hip, and other
joint replacement surgery;
ophthalmology; psychopharmacology;
registries; rheumatology; screening and
diagnostic testing analysis; and stroke.
We also need experts in biostatistics in
clinical settings, cardiovascular
epidemiology, cost effectiveness
analysis, dementia, endocrinology,
geriatrics, gynecology, minority health,
observational research design, stroke,
epidemiology, and women’s health.
The nomination letter must include a
statement that the nominee is willing to
serve as a member of the MEDCAC and
appears to have no conflict of interest
that would preclude membership. We
are requesting that all curricula vitae
include the following:
• Date of birth.
• Place of birth.
• Social security number.
• Title and current position.
• Professional affiliation.
• Home and business address.
• Telephone and fax numbers.
• E-mail address.
• List of areas of expertise.
In the nominations letter, we are
requesting that the nominee specify
whether applying for a Voting position
or Industry Representative. Potential
candidates will be asked to provide
detailed information concerning such
matters as financial holdings,
consultancies, and research grants or
contracts in order to permit evaluation
of possible sources of conflict of
interest.
VerDate Nov<24>2008
18:52 Sep 24, 2009
Jkt 217001
Members are invited to serve for
overlapping 2-year terms. A member
may serve after the expiration of the
member’s term until a successor takes
office. Any interested person may
nominate one or more qualified persons.
Self-nominations are also accepted.
The current Secretary’s Charter for the
MEDCAC is available on the CMS Web
site at: https://www.cms.hhs.gov/FACA/
Downloads/medcaccharter.pdf, or you
may obtain a copy of the charter by
submitting a request to the contact listed
in the FOR FURTHER INFORMATION section
of this notice.
Authority: 5 U.S.C. App. 2, section 10(a)(1)
and (a)(2).
(Catalog of Federal Domestic Assistance
Program No. 93.773, Medicare—Hospital
Insurance; and Program No. 93.774,
Medicare—Supplementary Medical
Insurance Program)
Dated: September 21, 2009.
Barry M. Straube,
CMS Chief Medical Officer, Director, Office
of Clinical Standards and Quality, Centers
for Medicare & Medicaid Services.
[FR Doc. E9–23257 Filed 9–24–09; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Notice of Listing of Members of the
National Institutes of Health’s Senior
Executive Service 2009 Performance
Review Board (PRB)
The National Institutes of Health
(NIH) announces the persons who will
serve on the National Institutes of
Health’s Senior Executive Service 2009
Performance Review Board. This action
is being taken in accordance with Title
5, U.S.C., Section 4314(c)(4), which
requires that members of performance
review boards be appointed in a manner
to ensure consistency, stability, and
objectivity in performance appraisals
and requires that notice of the
appointment of an individual to serve as
a member be published in the Federal
Register.
The following persons will serve on
the NIH Performance Review Board,
which oversees the evaluation of
performance appraisals of NIH Senior
Executive Service (SES) members: Ms.
Colleen Barros (Chair); Dr. Michael
Gottesman; Ms. Lenora Johnson; Ms.
Robin Kawazoe; Dr. Raynard Kington;
Ms. Janis Mullaney; Dr. Sally Rockey.
For further information about the NIH
Performance Review Board, contact the
Office of Human Resources, Workforce
Relations Division, National Institutes of
PO 00000
Frm 00093
Fmt 4703
Sfmt 4703
48993
Health, Building 31, Room B3C07,
Bethesda, Maryland 20892, telephone
301–402–9203 (not a toll-free number).
Dated: September 20, 2009.
Francis S. Collins,
Director, National Institutes of Health.
[FR Doc. E9–23265 Filed 9–24–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0026]
Apothecon et al.; Withdrawal of
Approval of 103 New Drug
Applications and 35 Abbreviated New
Drug Applications; Correction
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; correction.
SUMMARY: The Food and Drug
Administration (FDA) is correcting a
notice that appeared in the Federal
Register of February 11, 2009 (74 FR
6896). The document announced the
withdrawal of approval of 103 new drug
applications (NDAs) and 35 abbreviated
new drug applications (ANDAs). The
document published with an error in
the identification of the ANDA for
Amiodarone Hydrochloride Injection,
50 milligrams/milliliter, held by
Hospira, Inc. This document corrects
that error.
DATES:
Effective March 13, 2009.
FOR FURTHER INFORMATION CONTACT:
Florine P. Purdie, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 6366,
Silver Spring, MD 20993–0002, 301–
796–3601.
In FR Doc.
E9–2901, appearing on page 6896 in the
Federal Register of Wednesday,
February 11, 2009, the following
correction is made:
On page 6900, in the first column of
the table, third item from the bottom of
the page, the entry ‘‘ANDA 75–108’’ is
corrected to read ‘‘ANDA 76–108’’.
SUPPLEMENTARY INFORMATION:
Dated: September 9, 2009.
Douglas C. Throckmorton,
Deputy Director, Center for Drug Evaluation
and Research.
[FR Doc. E9–23170 Filed 9–24–09; 8:45 am]
BILLING CODE 4160–01–S
E:\FR\FM\25SEN1.SGM
25SEN1
]]>Agencies
[Federal Register Volume 74, Number 185 (Friday, September 25, 2009)]
[Notices]
[Page 48993]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-23170]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2009-N-0026]
Apothecon et al.; Withdrawal of Approval of 103 New Drug
Applications and 35 Abbreviated New Drug Applications; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is correcting a notice
that appeared in the Federal Register of February 11, 2009 (74 FR
6896). The document announced the withdrawal of approval of 103 new
drug applications (NDAs) and 35 abbreviated new drug applications
(ANDAs). The document published with an error in the identification of
the ANDA for Amiodarone Hydrochloride Injection, 50 milligrams/
milliliter, held by Hospira, Inc. This document corrects that error.
DATES: Effective March 13, 2009.
FOR FURTHER INFORMATION CONTACT: Florine P. Purdie, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 6366, Silver Spring, MD 20993-0002, 301-
796-3601.
SUPPLEMENTARY INFORMATION: In FR Doc. E9-2901, appearing on page 6896
in the Federal Register of Wednesday, February 11, 2009, the following
correction is made:
On page 6900, in the first column of the table, third item from the
bottom of the page, the entry ``ANDA 75-108'' is corrected to read
``ANDA 76-108''.
Dated: September 9, 2009.
Douglas C. Throckmorton,
Deputy Director, Center for Drug Evaluation and Research.
[FR Doc. E9-23170 Filed 9-24-09; 8:45 am]
BILLING CODE 4160-01-S
